Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Company Overview - Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV) and has a broad portfolio that includes drugs for liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases [12] - The company's flagship treatment, Biktarvy, is driving growth within its strong HIV franchise, which generated total sales of $19.6 billion in 2024, reflecting an 8% year-over-year increase [12] Investment Ratings - Gilead Sciences holds a 2 (Buy) rating on the Zacks Rank, indicating a favorable investment outlook [13] - The company has a VGM Score of A, suggesting strong overall performance across value, growth, and momentum metrics [13] Momentum and Earnings Estimates - Gilead has a Momentum Style Score of B, with shares increasing by 3.6% over the past four weeks [13] - Two analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate rising by $0.01 to $7.92 per share [13] - The company boasts an average earnings surprise of +16.5%, indicating a history of exceeding earnings expectations [13] Conclusion - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Gilead Sciences is positioned as a strong candidate for investors seeking potential growth opportunities [14]